Anti-CD46 antibodies and methods of use
US12252746B2 · kind B2 · utility
0Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2022 |
| Grant date | Mar 18, 2025 |
| Priority date | — |
| Expiry date | Jul 27, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.